Abbott Labs: Steadily Getting Back To Normal

Summary:

  • Abbott has had a crazy couple of years, with a formula recall and a COVID testing boom.
  • Through this year, most of that should start to normalize, and the Libre 3 launch and growth in the diabetes market should remain a long-term tailwind for the company.
  • Abbott is a fine hold for dividend safety, but I’d prefer to look elsewhere.

Families Struggle To Find Baby Formula As Shortage Worsens Across The Nation

Nathan Howard

Abbott Labs (NYSE:ABT) is in a tough spot to analyze, with a lot of moving parts. The company was at the center of a boom in COVID testing, faced a formula recall at the end of last year, and recently launched

returns over time

FAST Graphs

Recent results

Company filing

Chart
Data by YCharts

ROIC-WACC spreads

GuruFocus

Chart
Data by YCharts

EArnings over time

FAST Graphs

returns with stable multiple

FAST Graphs

retusn with multiple expansion

FAST Graphs


Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.


Leave a Reply

Your email address will not be published. Required fields are marked *